StreetInsider.com News Articles

Greenwich LifeSciences reports 33% increase in FLAMINGO-01 screening rate

Tue, 03 Mar 2026 06:01:02 -0500

Greenwich LifeSciences Inc. (NASDAQ: GLSI) reported that patient screening rates for its Phase III FLAMINGO-01 clinical trial increased to over 800 patients per year, representing a 33% increase from the previously reported annual screen rate of 600 patients per year.

The clinical-stage biopharmaceutical company achieved its highest screening rate of approximately 200 patients per quarter over the past six months across US and European sites. The company attributed this increase to new sites activated in 2025 and increased patient momentum at existing sites.

More than 1,000 patients have been screened for the study, which is evaluating GLSI-100, an immunotherapy designed to prevent

Greenwich LifeSciences reports 33% increase in FLAMINGO-01 screening rate

Tue, 03 Mar 2026 06:01:02 -0500

More than 1,000 patients have been screened for the study, which is evaluating GLSI-100, an immunotherapy designed to prevent

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Tue, 03 Mar 2026 06:00:00 -0500

STAFFORD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on the increased patient screen rate in FLAMINGO-01.

FLAMINGO-01 Annual Patient Screen Rate Increases to Over 800 Patients per Year

Over the past 6 months, the Company achieved its highest screening rate of approximately 200 patients per quarter or the equivalent of over 800 patients per year in

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Tue, 03 Mar 2026 06:00:00 -0500

FLAMINGO-01 Annual Patient Screen Rate Increases to Over 800 Patients per Year

Over the past 6 months, the Company achieved its highest screening rate of approximately 200 patients per quarter or the equivalent of over 800 patients per year in

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

Tue, 24 Feb 2026 06:01:23 -0500

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, including two corresponding posters.

The AACR 2026 conference will be held from April 17-22, 2026. The AACR plans to publish the abstract titles on March 17, 2026 at 4:30 pm EST, the abstracts on April 17, 2026 at 3:00 pm EST, and the posters on the

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

Tue, 24 Feb 2026 06:00:00 -0500

STAFFORD, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that two abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, including two corresponding posters.

The AACR 2026 conference will be held from April 17-22, 2026. The AACR plans to publish the abstract titles on March 17, 2026 at 4:30 pm EST, the

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

Tue, 24 Feb 2026 06:00:00 -0500

The AACR 2026 conference will be held from April 17-22, 2026. The AACR plans to publish the abstract titles on March 17, 2026 at 4:30 pm EST, the

H.C. Wainwright Reiterates Buy Rating on Greenwich LifeSciences (GLSI)

Thu, 05 Feb 2026 06:50:21 -0500

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $50.00 price target on Greenwich LifeSciences (NASDAQ: GLSI).

The analyst commented: "Last week, Greenwich LifeSciences provided an update on its cash burn rate and financing strategy. At the end of December 2025, the company had $6M in cash. The company raised approximately $7M via its ATM facility during the first three weeks of January 2026, bringing the cash position to $12.5M as of January 23, 2026. Given the annual burn rate of $9.5M in 2025 and the modest increase in cash burn rate in 2026, management expects the current cash balance

Greenwich LifeSciences raises cash balance to $12.5 million through ATM

Tue, 27 Jan 2026 06:00:42 -0500

Greenwich LifeSciences Inc. (NASDAQ: GLSI) reported its cash balance increased to approximately $12.5 million as of January 23, 2026, after raising about $7 million in the first three weeks of January through its at-the-market financing facility.

The clinical-stage biopharmaceutical company said its 2025 cash burn rate was approximately $9.5 million, while ATM financing proceeds for 2025 exceeded this amount, resulting in a year-end cash balance of about $6 million as of December 31, 2025. The preliminary financial figures are unaudited and subject to change pending completion of the company's 2025 financial audit.

CEO Snehal Patel stated the current cash balance could exceed

Greenwich LifeSciences raises cash balance to $12.5 million through ATM

Tue, 27 Jan 2026 06:00:42 -0500

CEO Snehal Patel stated the current cash balance could exceed

Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

Tue, 27 Jan 2026 06:00:00 -0500

STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on its cash burn rate and financing strategy.

The Company's ATM financing vehicle allows the Company to sell its common stock directly into the trading market at market price. The amount raised through our ATM for 2025 exceeded the Company's 2025 cash burn rate of approximately $9.5 million, leading to

Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

Tue, 27 Jan 2026 06:00:00 -0500

FDA approves Greenwich LifeSciences commercial GP2 for FLAMINGO-01 trial

Thu, 22 Jan 2026 06:00:15 -0500

Greenwich LifeSciences Inc. (NASDAQ: GLSI) announced that the FDA has approved the use of the first commercial lot of GP2 vials in its Phase III FLAMINGO-01 clinical trial.

The company manufactured three commercial lots of GP2 active ingredient in 2023 at an approved commercial facility, capable of producing approximately 200,000 doses. In 2024, the first of three commercial lots was filled into vials for commercial sale or clinical use at a commercial facility.

CEO Snehal Patel stated the company plans to begin using the new GP2 vials at all 40 US sites in the coming weeks. The company has three years of

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

Thu, 22 Jan 2026 06:00:00 -0500

STAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of commercially manufactured GP2 in FLAMINGO-01.

FDA Reviews and Approves Use of 1^st GP2 Commercial Lot in FLAMINGO-01

The first three commercial lots of GP2 active ingredient were manufactured in 2023 in an approved commercial facility, which could be used to prepare approximately 200,000 doses of GP2.

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

Thu, 22 Jan 2026 06:00:00 -0500

FDA Reviews and Approves Use of 1^st GP2 Commercial Lot in FLAMINGO-01

The first three commercial lots of GP2 active ingredient were manufactured in 2023 in an approved commercial facility, which could be used to prepare approximately 200,000 doses of GP2.

Form 4 Greenwich LifeSciences, For: Jan 13 Filed by: Patel Snehal

Thu, 15 Jan 2026 06:07:00 -0500

si-local-file:///var/storage/secattach/20260115/25851847.html

Form 4 Greenwich LifeSciences, For: Jan 13 Filed by: Patel Snehal

Thu, 15 Jan 2026 06:07:00 -0500

si-local-file:///var/storage/secattach/20260115/25851847.html

Form 4 Greenwich LifeSciences, For: Jan 12 Filed by: Patel Snehal

Wed, 14 Jan 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260114/25846214.html

Form 4 Greenwich LifeSciences, For: Jan 12 Filed by: Patel Snehal

Wed, 14 Jan 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260114/25846214.html

Form 4 Greenwich LifeSciences, For: Dec 31 Filed by: Patel Snehal

Mon, 05 Jan 2026 06:07:00 -0500

si-local-file:///var/storage/secattach/20260105/25800826.html

Form 4 Greenwich LifeSciences, For: Dec 31 Filed by: Patel Snehal

Mon, 05 Jan 2026 06:07:00 -0500

si-local-file:///var/storage/secattach/20260105/25800826.html

Form 4 Greenwich LifeSciences, For: Dec 30 Filed by: Patel Snehal

Fri, 02 Jan 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260102/25795974.html

Form 4 Greenwich LifeSciences, For: Dec 30 Filed by: Patel Snehal

Fri, 02 Jan 2026 06:05:00 -0500

si-local-file:///var/storage/secattach/20260102/25795974.html

Greenwich LifeSciences (GLSI) PT Raised to $50 at H.C. Wainwright

Tue, 30 Dec 2025 06:10:45 -0500

H.C. Wainwright analyst Yi Chen raised the price target on Greenwich LifeSciences (NASDAQ: GLSI) to $50.00 (from $39.00) while maintaining a Buy rating.

Greenwich LifeSciences extends director lock-up to September 2026

Mon, 29 Dec 2025 06:01:12 -0500

Greenwich LifeSciences Inc. (NASDAQ: GLSI) announced that its board of directors has extended the lock-up period for shares owned by company directors, officers, and existing pre-IPO investors to September 30, 2026. The extension represents approximately 72 months from the company's initial public offering date.

During this period, current officers, directors and certain shareholders will not be able to sell their shares of common stock unless modified by the board of directors. After September 30, 2026, the quantity of locked-up shares available for daily sale will be restricted under a leak-out plan unless otherwise modified by the board.

CEO Snehal Patel stated that